目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T62872 | |||
PDGFR-IN-1 (compound 7m) 是一种口服具有活力的 PDGFR (血小板源性生长因子受体) 抑制剂,作用于 PDGFRα (IC50: 2.4 nM) 和 PDGFRβ (IC50: 0.9 nM)。。PDGFR-IN-1 表现出较强的抗肿瘤作用,并毒性较低,能够用于研究骨肉瘤。 | |||
T62621 | |||
pan-HER-IN-2 (Compound C6) 是一种口服具有活力的、可逆的广谱 HER 抑制剂,能够作用于 EGFR (IC50: 0.72 nM)、HER4 (IC50: 2.0 nM)、EGFRT790M (IC50: 8.2 nM) / L858R (IC50: 75.1 nM)。pan-HER-IN-2 可以诱导细胞凋亡 (apoptosis),具有抗肿瘤作用。 | |||
T64253 | |||
EGFR/HER2-IN-4 是一种不可逆的、口服具有活力的双重抑制剂,能够抑制 EGFR 的活性 (IC50: 0.6 nM)。EGFR/HER2-IN-4 对 L858R 和 T790M 突变显示出有效的 EGFR 激酶抑制活性。EGFR/HER2-IN-4 在体内表现出明显的抗肿瘤作用,能够用于研究肺癌。 | |||
T62366 | |||
TH-6 是一种 HDAC 的有效抑制剂,能够作用于 HDAC1 (IC50: 0.115 μM)、HDAC2 (IC50: 0.135 μM)、HDAC3 (IC50: 0.242 μM)、HDAC6 (IC50: 0.138 μM)、HDAC8 (IC50: 2.120 μM)。TH-6 能够将细胞周期阻滞在 G2/M 期,诱导细胞凋亡。TH-6 对细胞迁移和侵袭具有抑制作用,表现出抗肿瘤作用。 | |||
T62076 | |||
LPM4870108 是一种有效的、口服具有活力的泛 Trk (WT/MT) 抑制剂,能够作用于 TrkC (IC50: 0.2 nM)、TrkA (IC50: 2.4 nM)、TrkAG595R (IC50: 3.5 nM) 和 TrkAG667C (IC50: 2.3 nM),且对 Trk 的选择性高于 ALK (IC50: 182 nM)。LPM4870108 显示出抗肿瘤效果。 | |||
T62108 | |||
ErSO-DFP 是一种预期的未折叠蛋白反应 (a-UPR) 激活剂。ErSO-DFP 能够提高对雌激素受体α+ (ERα+) 癌细胞的选择性,选择性高于 ErSO。ErSO-DFP 具有抗肿瘤作用,能够明显消除小鼠模型中 MCF-7 肿瘤。 | |||
T62118 | |||
KIF18A-IN-4 是一种中度有效的 ATP 和微管 (microtubule) 非竞争性 KIF18A 抑制剂,其 IC50 值为 6.16 μM。KIF18A-IN-4 能够选择性的作用于大量有丝分裂驱动蛋白和激酶,对微管蛋白组装无直接影响。KIF18A-IN-4 显示出抗肿瘤作用。 | |||
T62772 | |||
TPB15 是一种口服具有活力的 Hh(Hedgehog) 信号抑制剂。TPB15 可以明显阻滞 MDA-MB-468 细胞周期,并诱导其凋亡。TPB15 阻断 Smo(Smoothened) 转位到纤毛中,减少 Smo 蛋白和 mRNA 表达。TPB15 对下游调控因子胶质瘤相关癌基因1 (Gli1) 的表达表现出抑制作用。TPB15 具有较好的抗肿瘤作用,且毒性较低。 | |||
T64022 | |||
Antitumor agent-37 表现出有效的抗增殖和抗转移效果。Antitumor agent-37 能够诱导严重的 DNA 损伤,进而导致 γ-H2AX 和 p53 的高表达。Antitumor agent-37 可利用线粒体凋亡通路 Bcl-2/Bax/caspase3,诱导肿瘤细胞凋亡 (apoptosis)。Antitumor agent-37 可以抑制 PD-L1 的表达,提高肿瘤组织中 CD3+ 和 CD8+ T 浸润细胞,明显改善免疫反应。 | |||
T62822 | |||
CT1-3 是一种有效的抗癌剂。CT1-3 能够调控 JNK/Bcl-2/Bax/XIAP 通路,进而诱导线粒体介导的细胞凋亡 (apoptosis)。CT1-3 可以调控 E-cadherin/Snail 轴抑制人癌细胞 (HCCs) 的上皮间充质转化 (EMT) 电位,并抑制肿瘤发生。CT1-3 在小鼠模型中具有抗肿瘤作用,且没有表现出明显的肝、肾毒性。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPK-00491 | IL-18BP Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.
|
|||||
TMPK-00492 | IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated | Cynomolgus | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.
|
|||||
TMPK-00082 | IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 20.5 kDa and the accession number is O95998-2.
|
|||||
TMPK-00456 | IGF1R/CD221 Protein, Human, Recombinant (aa 31-932, His & Avi), Biotinylated | Human | HEK293 Cells | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Human, Recombinant (aa 31-932, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 105.8 kDa (alpha subunit) and 23 kDa (beta subunit) and the accession number is P08069.
|
|||||
TMPK-00455 | IGF1R/CD221 Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 105.8 kDa (alpha subunit) and 23 kDa (beta subunit) and the accession number is P08069.
|
|||||
TMPK-00658 | IGF1R/CD221 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target. IGF1R/CD221 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 80.59 kDa (alpha subunit) and 19.28 kDa (beta subunit) and the accession number is G7P9I7.
|